The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up

The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up

A randomized, controlled clinical trial established the efficacy and safety of short‐term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long‐term hydroxyurea usage, patients in this trial were followed for 17.5 years during which they could start or stop hydrox...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology 2010-06, Vol.85 (6), p.403-408
Hauptverfasser: Steinberg, Martin H., McCarthy, William F., Castro, Oswaldo, Ballas, Samir K., Armstrong, F. Danny, Smith, Wally, Ataga, Kenneth, Swerdlow, Paul, Kutlar, Abdullah, DeCastro, Laura, Waclawiw, Myron A.
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Anemia, Sickle Cell - complications
Anemia, Sickle Cell - drug therapy
Anemia, Sickle Cell - mortality
Anemias. Hemoglobinopathies
Biological and medical sciences
Diseases of red blood cells
DNA Damage
Drug Utilization
Early Termination of Clinical Trials
Female
Follow-Up Studies
Hematologic and hematopoietic diseases
Humans
Hydroxyurea - adverse effects
Hydroxyurea - therapeutic use
Kidney Diseases - mortality
Liver Diseases - mortality
Lung Diseases - mortality
Male
Medical sciences
Middle Aged
Neoplasms - mortality
Practice Patterns, Physicians
Prospective Studies
Risk Assessment
Sepsis - mortality
Statistics, Nonparametric
Stroke - mortality
Survival Analysis
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A randomized, controlled clinical trial established the efficacy and safety of short‐term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long‐term hydroxyurea usage, patients in this trial were followed for 17.5 years during which they could start or stop hydroxyurea. The purpose of this follow‐up was to search for adverse outcomes and estimate mortality. For each outcome and for mortality, exact 95% confidence intervals were calculated, or tests were conducted at α = 0.05 level (P‐value
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.21699